Kv7 channel activators compositions and methods of use

Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 15. Aug. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

BOZIK MICHAEL E [VerfasserIn]
HARRIED SCOTT S [VerfasserIn]
RESNICK LYNN [VerfasserIn]
TOPALOV GEORGE T [VerfasserIn]
BELARDI JUSTIN K [VerfasserIn]
FLENTGE CHARLES A [VerfasserIn]
MARESKA DAVID A [VerfasserIn]
HALE JAMES S [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
C07D: Heterocyclic compounds (macromolecular compounds c0 (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-08-15, Last update posted on www.tib.eu: 2024-02-23, Last updated: 2024-03-01

Patentnummer:

US11724990

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA018772048